Biogen Pharmachem Industries Inc Stock Price Today (NSE: BIOGEN)
Fundamental Score
Biogen Pharmachem Industries Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biogen Pharmachem Industries Inc share price today is ₹0.36, up +2.86% on NSE/BSE as of 22 June 2026. Biogen Pharmachem Industries Inc (BIOGEN) is a Small-cap company in the Other Financial Services sector with a market capitalisation of ₹68.60 (Cr). The 52-week high for BIOGEN share price is ₹1.08 and the 52-week low is ₹0.34. At a P/E ratio of 39.88x, BIOGEN is currently trading above its industry average P/E of 30.94x. The company has a Return on Equity (ROE) of -0.39% and a debt-to-equity ratio of 0.00.
Biogen Pharmachem Industries Inc Share Price Chart — NSE/BSE Historical Performance
Biogen Pharmachem Industries Inc share price chart: -28.00% return over the past month. 52-week high ₹1.08, 52-week low ₹0.34.
Biogen Pharmachem Industries Inc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹0.35 | ₹0.36 | ₹0.35 | ₹0.36 | 20.94L (Cr) | |
| ₹0.36 | ₹0.36 | ₹0.35 | ₹0.35 | 36.23L (Cr) | |
| ₹0.36 | ₹0.36 | ₹0.35 | ₹0.36 | 27.95L (Cr) | |
| ₹0.35 | ₹0.36 | ₹0.34 | ₹0.36 | 44.52L (Cr) | |
| ₹0.36 | ₹0.36 | ₹0.34 | ₹0.36 | 63.90L (Cr) | |
| ₹0.36 | ₹0.37 | ₹0.34 | ₹0.36 | 92.73L (Cr) | |
| ₹0.37 | ₹0.37 | ₹0.36 | ₹0.37 | 23.31L (Cr) | |
| ₹0.38 | ₹0.38 | ₹0.36 | ₹0.37 | 34.80L (Cr) | |
| ₹0.39 | ₹0.39 | ₹0.37 | ₹0.37 | 102.40L (Cr) | |
| ₹0.39 | ₹0.40 | ₹0.38 | ₹0.39 | 54.78L (Cr) |
Biogen Pharmachem Industries Inc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹0.36 | ₹0.36 | ₹0.35 | ₹0.36 | +0.00% | |
| ₹0.47 | ₹0.50 | ₹0.34 | ₹0.36 | -23.40% | |
| ₹0.52 | ₹0.65 | ₹0.46 | ₹0.47 | -9.62% | |
| ₹0.67 | ₹0.67 | ₹0.50 | ₹0.51 | -23.88% | |
| ₹0.79 | ₹0.84 | ₹0.64 | ₹0.67 | -15.19% | |
| ₹0.70 | ₹0.80 | ₹0.57 | ₹0.59 | -15.71% | |
| ₹0.76 | ₹0.77 | ₹0.68 | ₹0.69 | -9.21% | |
| ₹0.83 | ₹0.84 | ₹0.75 | ₹0.76 | -8.43% | |
| ₹0.83 | ₹0.90 | ₹0.80 | ₹0.82 | -1.20% | |
| ₹0.88 | ₹0.94 | ₹0.78 | ₹0.83 | -5.68% | |
| ₹0.92 | ₹0.94 | ₹0.87 | ₹0.89 | -3.26% | |
| ₹0.96 | ₹1.08 | ₹0.91 | ₹0.92 | -4.17% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Bonus issue is a smokescreen for a fundamentally weak micro-cap; exit before the music stops.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Biogen Pharmachem Industries has announced a 1:6 bonus share issue, with a record date of May 15, 2026. Shareholders need to approve this via postal ballot and e-voting, which is open until April 25, 2026. Trading window closed on April 1, 2026, until 48 hours after FY26 results are released.
CORE STORY (THE REAL GAME)
Bonus issue play in a micro-cap. Market expects rapid growth and increased investor interest post-bonus issue, despite underlying business being trading in shares and securities.
- Bonus issue record date approaching (May 15, 2026)
- Low stock price attracts retail speculation
- Postal ballot for bonus issue approval ongoing
- Shareholder approval of bonus issue
- Increased trading volume post-bonus issue
- Positive news flow (unlikely)
- Micro-cap with ₹68.6 Cr market cap
- Zero promoter holding
- Negative ROE and ROCE
- Illiquidity risk
No FII or DII holding. Zero promoter holding suggests lack of confidence.
NBFC sector is growing, but this company is too small to benefit significantly.
Free cash flow is positive at ₹7.91 Cr, but profitability is weak.
Bonus issue might provide a short-term boost, but the lack of fundamental strength will eventually lead to a correction. Avoid holding for the long term.
Primary Thesis Risk
Illiquidity and lack of promoter holding make this a high-risk speculation.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Biogen Pharmachem Industries Inc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biogen Pharmachem Industries Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOGEN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (51.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-0.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.39%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.26%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Biogen Pharmachem Industries Inc vs Other Financial Services Peers
Peer Comparison - Other Financial Services
Compare Biogen Pharmachem Industries Inc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Biogen Pharmachem Industries IncBiogen Pharmach...Selected✓ BIOGEN • 531752 | 13.5/100 | ₹0.36₹0 | ₹68.60₹68.60 | 39.88Average 39.9 Average | -0.39%Poor -0.39% Poor | -0.39%Poor -0.39% Poor | 0.00Excellent 0.0 Excellent | — — | — — | 0.00% |
Crisil LtdCrisil Ltd... CRISIL • 500092 | 64/100 | ₹3987.30₹3987 | ₹32833.08₹32833.08 | 43.82Average 43.8 Average | 27.81%Excellent 27.81% Excellent | 35.60%Excellent 35.60% Excellent | 0.11Excellent 0.1 Excellent | 14.43%Good 14.43% Good | 13.49%Good 13.49% Good | 0.56% |
RRPSemiconductorRRPSemiconducto... RRPS • 504346 | 21.2/100 | ₹11320.20₹11320 | ₹15422.64₹15422.64 | — — | 208.63%Excellent 208.63% Excellent | 80.21%Excellent 80.21% Excellent | 1.56Average 1.6 Average | 179.71%Excellent 179.71% Excellent | — — | 0.00% |
COLAB PLATFORMS LIMITEDCOLAB PLATFORMS... COLAB • 542866 | 53.3/100 | ₹153.55₹154 | ₹4011.66₹4011.66 | 864.58Average 864.6 Average | 12.36%Average 12.36% Average | 16.59%Good 16.59% Good | 0.00Excellent 0.0 Excellent | 79.86%Excellent 79.86% Excellent | 188.59%Excellent 188.59% Excellent | 0.01% |
Dhani Services LtdDhani Services ... DHANI • 532960 | 20.9/100 | ₹51.06₹51 | ₹3896.81₹3896.81 | 114.92Average 114.9 Average | -1.81%Poor -1.81% Poor | 1.39%Poor 1.39% Poor | 0.18Excellent 0.2 Excellent | — — | -32.89%Poor -32.89% Poor | 0.00% |
ALGOQUANTALGOQUANT... ALGOQUANT • 505725 | 6.9/100 | ₹56.73₹57 | ₹1689.95₹1689.95 | 102.86Average 102.9 Average | 37.55%Excellent 37.55% Excellent | 32.47%Excellent 32.47% Excellent | 0.24Excellent 0.2 Excellent | — — | — — | 0.00% |
LKP Finance LtdLKP Finance Ltd... LKPFIN • 507912 | 1.7/100 | ₹189.35₹189 | ₹1396.38₹1396.38 | — — | -0.17%Poor -0.17% Poor | -0.83%Poor -0.83% Poor | 0.06Excellent 0.1 Excellent | 14.57%Good 14.57% Good | -17.45%Poor -17.45% Poor | 0.00% |
Centrum Capital LtdCentrum Capital... CENTRUM • 501150 | 0/100 | ₹22.65₹23 | ₹1369.10₹1369.10 | — — | -57.60%Poor -57.60% Poor | 8.93%Poor 8.93% Poor | 37.49Poor 37.5 Poor | — — | 47.25%Excellent 47.25% Excellent | 0.00% |
67.9/100 | ₹912.60₹913 | ₹1086.24₹1086.24 | 32.77Average 32.8 Average | 28.60%Excellent 28.60% Excellent | 37.87%Excellent 37.87% Excellent | 0.00Excellent 0.0 Excellent | 94.13%Excellent 94.13% Excellent | 43.40%Excellent 43.40% Excellent | 1.94% | |
Prime Securities LtdPrime Securitie... PRIMESECU • 500337 | 49/100 | ₹284.70₹285 | ₹998.77₹998.77 | 30.04Average 30.0 Average | 19.46%Good 19.46% Good | 22.62%Excellent 22.62% Excellent | 0.01Excellent 0.0 Excellent | 34.59%Excellent 34.59% Excellent | 3.63%Average 3.63% Average | 0.51% |
39.1/100 | ₹290.00₹290 | ₹890.53₹890.53 | 39.02Average 39.0 Average | 25.18%Excellent 25.18% Excellent | 29.45%Excellent 29.45% Excellent | 0.27Excellent 0.3 Excellent | — — | — — | 0.00% | |
Top Other Financial Services Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Crisil Ltd share price32833.08 Cr
- RRPSemiconductor share price15422.64 Cr
- COLAB PLATFORMS LIMITED share price4011.66 Cr
- Dhani Services Ltd share price3896.81 Cr
- ALGOQUANT share price1689.95 Cr
Biogen Pharmachem Industries Inc Quarterly Performance
Latest quarterly metrics for BIOGEN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
51.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Biogen Pharmachem Industries Inc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BIOGEN — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Biogen Pharmachem Industries Inc Financial Statements
Annual income statement, balance sheet and cash flow for Biogen Pharmachem Industries Inc (BIOGEN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Biogen Pharmachem Industries Inc
About BIOGEN (Biogen Pharmachem Industries Inc)
Biogen Pharmachem Industries Inc (BIOGEN) is an emerging entity operating within the multifaceted realm of Other Financial Services, strategically positioned to leverage opportunit...ies in the dynamic financial landscape. Although relatively new under its current moniker since rebranding in March 2021, BIOGEN is actively carving a niche for itself by focusing on a diverse portfolio of financial activities beyond conventional banking or insurance models. The company concentrates on specialized financial solutions, potentially encompassing areas like investment management, capital market advisory, or bespoke financial instruments tailored to specific client needs. Its core strategy emphasizes a client-centric approach, seeking to deliver value through innovative and adaptive financial strategies designed to thrive in evolving market conditions. Based in Rajkot, India, BIOGEN harnesses a deep understanding of local market dynamics while simultaneously seeking to establish a broader national and potentially international footprint. The company operates with a commitment to transparency and ethical conduct, building trust with stakeholders through diligent risk management practices and adherence to regulatory compliance. BIOGEN's leadership team brings a wealth of experience in financial markets, coupled with a forward-thinking vision that prioritizes sustainable growth and long-term value creation. By embracing technology and data-driven insights, BIOGEN aims to optimize its operational efficiency and deliver cutting-edge financial solutions that resonate with its target clientele. BIOGEN's strategic direction revolves around identifying and capitalizing on underserved segments within the financial ecosystem. This proactive approach enables the company to tailor its services to meet the unique requirements of its clients, fostering lasting partnerships and solidifying its position as a trusted financial service provider. As it continues to evolve, BIOGEN is dedicated to innovation, continually exploring new avenues to expand its service offerings and enhance its capabilities. The company prioritizes building a strong, resilient foundation that will support its long-term aspirations and enable it to navigate the complexities of the ever-changing financial landscape with confidence and agility.
Company Details
Key Leadership
Latest News
BIOGEN Share Price: Frequently Asked Questions
What is the current share price of Biogen Pharmachem Industries Inc?
Biogen Pharmachem Industries Inc (BIOGEN) trades at ₹0.36 on NSE and BSE. Market cap ₹68.60 (Cr). Educational data only.
What is the P/E ratio of Biogen Pharmachem Industries Inc?
Biogen Pharmachem Industries Inc has a P/E of 39.88x vs industry average 30.94x.
What is the Bull Run score for Biogen Pharmachem Industries Inc?
Biogen Pharmachem Industries Inc has a Bull Run score of 13.5/100 based on 25+ financial parameters.
Does Biogen Pharmachem Industries Inc pay dividends?
Biogen Pharmachem Industries Inc has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Biogen Pharmachem Industries Inc?
Biogen Pharmachem Industries Inc has ROE of -0.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Biogen Pharmachem Industries Inc?
Biogen Pharmachem Industries Inc has debt-to-equity of 0.00.
Is Biogen Pharmachem Industries Inc a good investment?
Bull Run gives Biogen Pharmachem Industries Inc a score of 13.5/100. This is not investment advice — consult a SEBI-registered advisor.